Federal Capture Intelligence

Top HHS research and development in biotechnology (except nanobiotechnology) contractors (NAICS 541714)

Contract actions: October 1, 2021 – September 10, 2026 Updated September 11, 2026 Department of Health and Human Services agency guide NAICS 541714 · Research and Development in Biotechnology (except Nanobiotechnology)
Latest 12 months
$1.7B
Net obligations · Up $290.9M vs. $1.4B preceding
Prime contractors
207
With positive obligations in the latest 12 months

Research the HHS federal contracting market for research and development in biotechnology (except nanobiotechnology) under NAICS 541714. Compare top federal contractors and market share, reported contract obligations and spending trends, funding-office attribution, recent award activity, contract types, competition, and procurement methods, observed contract vehicle usage, and potential recompete research leads.

Contract obligation trends for Research and Development in Biotechnology (except Nanobiotechnology) at the Department of Health and Human Services

Federal records show $12.0B in net obligations across 1,732 awards in Research and Development in Biotechnology (except Nanobiotechnology) at the Department of Health and Human Services from Oct 1, 2021 through Sep 10, 2026. This market accounts for 8.2% of $145.5B in agency-wide net prime contract obligations over the period shown. Latest 12-month net obligations increased 20.9% from $1.4B to $1.7B. 25 prime contractors accounted for at least 80% of positive obligations in that latest period.

Fiscal-year activity

FY26 is year-to-date through Sep 10, 2026; earlier years show complete fiscal-year totals.

FY26 year-to-date: $1.3B versus $599.3M through the same date in FY25 (+112.9%).
Net obligations · complete fiscal yearNet obligations · FY26 YTDContract actions
View fiscal-year data table
Fiscal yearNet obligationsContract actionsCoverage
FY2022$2.0B1,024Complete
FY2023$4.5B1,109Complete
FY2024$3.2B1,261Complete
FY2025$1.0B1,163Complete
FY2026$1.3B807YTD through Sep 10, 2026

Market at a glance

All reported prime contract awards
All-period net obligations
$12.0B
1,732 awards · 691 prime contractors
Latest 12-month movement
+20.9%
$1.7B vs. $1.4B
Leading eight prime share
56.0%
Share held by the eight leading prime contractors in the latest 12 months
View agency share, denominators, and set-aside reporting
Agency context
8.2% of $145.5B in agency-wide net obligations.
Set-aside share when reported
11.2% of 1,176 awards with reported set-aside status.
Set-aside reporting
132 set aside · 1,044 no set-aside · 556 not reported

What changed in the last 12 months?

Sep 11, 2025–Sep 10, 2026, compared with Sep 11, 2024–Sep 10, 2025.

Competitive shifts

22 contractors were first observed in this market during the latest 12 months
$263.9MLatest 12-month obligations
Contractor-level obligations and first-observed dates appear below. “First observed” applies only to this market and the period shown.
View 22 contractors
ContractorLatest 12 months
AMGEN USA INC lost the most market share
15.15%→7.23%−7.9 percentage points
The contractor now ranks #4 by positive obligations, based on 2 reported actions.
PPD DEVELOPMENT LP climbed the most in the contractor rankings
#54→#10Up 44 places
The contractor accounts for 2.3% of positive obligations across 11 reported actions.
SHIONOGI INC was the largest newly observed contractor
$156.1MLatest 12-month obligations
First observed in this market on Apr 6, 2026, the contractor now ranks #3 by positive obligations across 2 reported actions.

Award activity

View 6 additional material changes

Market structure

Top-five contractor share increased
35.4%→46.8%+11.4 percentage points
Contractors outside the top five now account for 53.2% of positive obligations.

Competitive shifts

MONOGRAM BIOSCIENCES, INC. recorded the largest net deobligation
$0→−$15.6M−$15.6M
The contractor now is unranked by positive obligations, based on 3 reported actions.
LUMOS DIAGNOSTICS, INC had no reported activity in the latest 12 months
$9.2M→$0No latest-period activity
It previously ranked #32 by positive obligations, based on 3 reported actions.

Buyer demand

Reported obligations through OFC ASST SEC FOR PREPARENESS RES increased
$42.1M→$126.2M+$84.1M
Latest-period activity spans 20 awards across 15 prime contractors.
Reported obligations through BARDA - ASPR / DAAPPO / BARDA DCMA decreased
$1.3B→$1.3B−$43.0M
Latest-period activity spans 160 awards across 95 prime contractors.
How these findings are calculated

Findings are selected from matched-period changes in obligations, share, rank, funding offices, concentration, reported set-asides, material award actions, and agency-peer outliers. Related signals are combined, and only material evidence-backed changes are shown. Review the full methodology.

Federal contract obligations by funding office

See how positive obligations were attributed across funding offices in the 12 months ending Sep 10, 2026.

74.8% of positive obligations were attributed to BARDA - ASPR / DAAPPO / BARDA DCMA. That represents $1.3B, down $43.0M from the preceding 12 months.

Latest 12-month share of positive obligations; the gray segment represents all other reported offices.

  1. BARDA - ASPR / DAAPPO / BARDA DCMA74.8% · $1.3B · down $43.0M
  2. NATIONAL INSTITUTES OF HEALTH NIAID11.4% · $192.1M · up $65.8M
  3. OFC ASST SEC FOR PREPARENESS RES7.5% · $126.2M · up $84.1M
  4. NATIONAL INSTITUTES OF HEALTH NIDA1.6% · $27.0M · down $3.2M
  5. FDA OFFICE OF ACQ GRANT SVCS0.97% · $16.3M · down $10.1M
  6. All other reported offices3.7% of positive obligations
View reported office rankings, comparisons, and evidence

USAspending assigns each award to a funding office. That office may differ from the requiring activity, program office, contracting office, individual buyer, or actual customer.

  1. Reported funding office

    BARDA - ASPR / DAAPPO / BARDA DCMA

    #1Rank unchanged

    Latest 12 months

    $1.3B

    74.8% of positive obligations

    Versus preceding 12 months

    −$43.0M

    95 active prime contractors · 160 awards

    View office comparison and evidence

    Reported obligations decreased 3.3% from $1.3B to $1.3B. The office’s share of positive obligations moved from 81.8% to 74.8%, a change of −7.0 percentage points.

    The latest period contains 274 actions across 160 awards and 22 newly active prime contractors. The preceding period contained 111 active prime contractors and 159 awards.

    Leading award-level changes

  2. Reported funding office

    NATIONAL INSTITUTES OF HEALTH NIAID

    #2Rank unchanged

    Latest 12 months

    $192.1M

    11.4% of positive obligations

    Versus preceding 12 months

    +$65.8M

    88 active prime contractors · 166 awards

    View office comparison and evidence

    Reported obligations increased 52.1% from $126.3M to $192.1M. The office’s share of positive obligations moved from 7.9% to 11.4%, a change of +3.5 percentage points.

    The latest period contains 265 actions across 166 awards and 27 newly active prime contractors. The preceding period contained 80 active prime contractors and 155 awards.

  3. Reported funding office

    OFC ASST SEC FOR PREPARENESS RES

    #3Rank unchanged

    Latest 12 months

    $126.2M

    7.5% of positive obligations

    Versus preceding 12 months

    +$84.1M

    15 active prime contractors · 20 awards

    View office comparison and evidence

    Reported obligations increased 199.7% from $42.1M to $126.2M. The office’s share of positive obligations moved from 2.6% to 7.5%, a change of +4.8 percentage points.

    The latest period contains 28 actions across 20 awards and 7 newly active prime contractors. The preceding period contained 21 active prime contractors and 22 awards.

  4. Reported funding office

    NATIONAL INSTITUTES OF HEALTH NIDA

    #4Rank unchanged

    Latest 12 months

    $27.0M

    1.6% of positive obligations

    Versus preceding 12 months

    −$3.2M

    21 active prime contractors · 33 awards

    View office comparison and evidence

    Reported obligations decreased 10.7% from $30.2M to $27.0M. The office’s share of positive obligations moved from 1.9% to 1.6%, a change of −0.3 percentage points.

    The latest period contains 55 actions across 33 awards and 9 newly active prime contractors. The preceding period contained 21 active prime contractors and 26 awards.

  5. Reported funding office

    FDA OFFICE OF ACQ GRANT SVCS

    #5Up 1 from #6

    Latest 12 months

    $16.3M

    0.97% of positive obligations

    Versus preceding 12 months

    −$10.1M

    59 active prime contractors · 75 awards

    View office comparison and evidence

    Reported obligations decreased 38.2% from $26.4M to $16.3M. The office’s share of positive obligations moved from 1.7% to 0.97%, a change of −0.7 percentage points.

    The latest period contains 97 actions across 75 awards and 22 newly active prime contractors. The preceding period contained 64 active prime contractors and 88 awards.

  6. Reported funding office

    NATIONAL INSTITUTES OF HEALTH NINDS

    #6Up 1 from #7

    Latest 12 months

    $14.8M

    0.88% of positive obligations

    Versus preceding 12 months

    −$3.6M

    3 active prime contractors · 3 awards

    View office comparison and evidence

    Reported obligations decreased 19.6% from $18.4M to $14.8M. The office’s share of positive obligations moved from 1.2% to 0.88%, a change of −0.3 percentage points.

    The latest period contains 3 actions across 3 awards and 1 newly active prime contractor. The preceding period contained 7 active prime contractors and 19 awards.

  7. Reported funding office

    NATIONAL INSTITUTES OF HEALTH NICHD

    #7Up 2 from #9

    Latest 12 months

    $9.6M

    0.57% of positive obligations

    Versus preceding 12 months

    +$7.1M

    23 active prime contractors · 51 awards

    View office comparison and evidence

    Reported obligations increased 274.8% from $2.6M to $9.6M. The office’s share of positive obligations moved from 0.16% to 0.57%, a change of +0.4 percentage points.

    The latest period contains 78 actions across 51 awards and 4 newly active prime contractors. The preceding period contained 23 active prime contractors and 57 awards.

  8. Reported funding office

    ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (ARPA-H)

    #8New to the positive-obligation ranking

    Latest 12 months

    $8.6M

    0.51% of positive obligations

    Versus preceding 12 months

    +$8.6M

    7 active prime contractors · 7 awards

    View office comparison and evidence

    Reported obligations rose from $0 to $8.6M. The office’s share of positive obligations moved from 0% to 0.51%, a change of +0.5 percentage points.

    The latest period contains 20 actions across 7 awards and 7 newly active prime contractors. The preceding period contained 0 active prime contractors and 0 awards.

  9. Reported funding office

    NATIONAL INSTITUTES OF HEALTH

    #9Down 4 from #5

    Latest 12 months

    $8.6M

    0.51% of positive obligations

    Versus preceding 12 months

    −$18.4M

    2 active prime contractors · 2 awards

    View office comparison and evidence

    Reported obligations decreased 68.2% from $27.0M to $8.6M. The office’s share of positive obligations moved from 1.7% to 0.51%, a change of −1.2 percentage points.

    The latest period contains 2 actions across 2 awards and 1 newly active prime contractor. The preceding period contained 5 active prime contractors and 7 awards.

  10. Reported funding office

    CDC OFFICE OF ACQUISITION SERVICES

    #10Down 2 from #8

    Latest 12 months

    $7.2M

    0.43% of positive obligations

    Versus preceding 12 months

    +$1.1M

    18 active prime contractors · 19 awards

    View office comparison and evidence

    Reported obligations increased 18.3% from $6.1M to $7.2M. The office’s share of positive obligations moved from 0.38% to 0.43%, a change of +0.1 percentage points.

    The latest period contains 30 actions across 19 awards and 7 newly active prime contractors. The preceding period contained 20 active prime contractors and 26 awards.

  11. Reported funding office

    ASPR BARDA DIV CONTRACTS MGMT & ACQ

    No positive-obligation rank

    Latest 12 months

    $0

    0% of positive obligations

    Versus preceding 12 months

    +$200.0M

    0 active prime contractors · 0 awards

    View office comparison and evidence

    Reported obligations moved from $200.0M in net deobligations to $0 in net obligations. The office’s share of positive obligations moved from 0% to 0%, a change of 0.0 percentage points.

    The latest period contains 0 actions across 0 awards. The preceding period contained 1 active prime contractor and 1 award.

    Leading award-level changes

Contract types, competition, and procurement methods

From Sep 11, 2025 through Sep 10, 2026, 308 awards had positive obligations totaling $1.8B. Np was the leading reported procedure, accounting for 48.3% of positive obligations. Awards with a reported parent IDV accounted for 12.6%. Reported awards used contract vehicles such as CARRRP and BARDA Nonclinical Development Biological.

Leading award type
87.1%
Definitive Contract
Leading reported procedure
48.3%
Np
Reported parent IDV
12.6%
of positive obligations had a reported parent IDV
Median reported offers
2
216 of 308 awards reported offers

Observed contract vehicles

Only exact reported parent-PIID matches are shown; missing parent IDs are not inferred.

Buying method changes

Compared with Sep 11, 2024–Sep 10, 2025. Based on 308 current awards and 368 preceding awards with positive net obligations.

Reported full-and-open obligation share
47.1%
Down from 92.0% in the preceding period
Median positive award obligations
$719K
Up from $300K in the preceding period
Parent-IDV obligation share
12.6%
Down from 36.9% in the preceding period
How to read these changes

Directional color and the Up or Down labels show historical movement only. Green does not mean favorable and red does not mean unfavorable; neither predicts a future procurement method.

Same-NAICS comparison

Compared with the NAICS 541714 peer median, parent-IDV obligation share is 35.4 percentage points lower, reported full-and-open obligation share is 36.5 percentage points higher, delivery-order obligation share is 35.4 percentage points lower, and median positive award obligations are 1849.7% higher.

MeasureThis marketPeer medianDifference
Parent-IDV obligation share12.6%48.0%-35.4 pts
Reported full-and-open obligation share47.1%10.7%+36.5 pts
Delivery-order obligation share12.6%48.0%-35.4 pts
Median positive award obligations$719K$37K+1849.7%
Peer cohort and comparison limits

The peer median gives each of the 3 eligible agency markets equal weight. The included agency markets are:

Agency mission, scale, and acquisition context can differ. Peer position does not establish market attractiveness or predict a future procurement method.

View buying-method details and data coverage

Award types

Reported valueAwardsPositive obligationsShare
Definitive Contract(D)125$1.5B87.1%
Delivery Order(C)133$222.0M12.6%
Purchase Order(B)49$5.2M0.29%
BPA Call(A)1$20K0%

Reported parent-award types

Reported valueAwardsPositive obligationsShare
IDC(B)132$221.7M12.6%
FSS(C)1$215K0.010%
BPA(E)1$20K0%
Not reported174$1.5B87.4%

Single- or multiple-award parent structure

Reported valueAwardsPositive obligationsShare
Single Award(S)93$199.1M11.3%
Multiple Award(M)41$22.9M1.3%
Not reported174$1.5B87.4%

Solicitation procedures

Reported valueAwardsPositive obligationsShare
Np(NEGOTIATED PROPOSAL/QUOTE)56$850.4M48.3%
Negotiated Proposal/Quote(NP)145$843.2M47.9%
Only One Source(SSS)7$24.5M1.4%
Subject to Multiple Award Fair Opportunity(MAFO)37$21.0M1.2%
Simplified Acquisition(SP1)33$5.3M0.30%
Sp1(SIMPLIFIED ACQUISITION)19$4.4M0.25%
Other reported values11$11.4M0.65%

Extent competed

Reported valueAwardsPositive obligationsShare
A(FULL AND OPEN COMPETITION)60$854.9M48.6%
Full and Open Competition(A)166$829.7M47.1%
Full and Open Competition After Exclusion of Sources(D)20$38.9M2.2%
Not Competed(C)7$24.5M1.4%
Competed Under SAP(F)14$4.1M0.23%
F(COMPETED UNDER SAP)13$3.7M0.21%
Other reported values28$4.5M0.25%

Fair-opportunity and limited-source reporting

Reported valueAwardsPositive obligationsShare
Fair Opportunity Given(FAIR)37$21.2M1.2%
Only One Source - Other(ONE)3$1.4M0.080%
Follow-on Action Following Competitive Initial Action(FOO)1$297K0.020%
Not reported267$1.7B98.7%

Other-than-full-and-open reasons

Reported valueAwardsPositive obligationsShare
Only One Source-Other (FAR 6.302-1 Other)(ONE)8$24.1M1.4%
Unique Source (FAR 6.302-1(B)(1))(UNQ)1$2.4M0.13%
SAP Non-Competition (FAR 13)(SP2)25$1.9M0.11%
Not reported274$1.7B98.4%

Contract pricing types

Reported valueAwardsPositive obligationsShare
U(COST PLUS FIXED FEE)25$520.1M29.6%
Cost Plus Fixed Fee(U)67$358.6M20.4%
Firm Fixed Price(J)88$259.3M14.7%
J(FIRM FIXED PRICE)34$212.3M12.1%
Cost Sharing(T)7$178.6M10.2%
Cost No Fee(S)61$98.1M5.6%
Other reported values26$133.1M7.6%

Product or Service Codes

Reported valueAwardsPositive obligationsShare
Health R&d Services; Health Care Services; Experimental Development(AN13)48$567.2M32.2%
Drugs and Biologicals(6505)13$351.6M20.0%
Health R&d Services; Health Care - Other; Applied Research(AN42)16$326.6M18.6%
Health R&d Services; Health Care Services; Applied Research(AN12)94$167.7M9.5%
Health R&d Services; Health Care Services; Basic Research(AN11)64$110.8M6.3%
Health R&d Services; Health Care Services; R&d Administrative Expenses(AN14)3$61.6M3.5%
Other reported values70$174.7M9.9%

Awarding subagencies

Reported valueAwardsPositive obligationsShare
Office of Assistant Secretary for Preparedness and Response(7505)76$1.4B82.1%
National Institutes of Health(7529)179$275.1M15.6%
Food and Drug Administration(7524)29$23.3M1.3%
Departmental Offices(1406)9$8.7M0.49%
Centers for Disease Control and Prevention(7523)14$7.2M0.41%
Indian Health Service(7527)1$215K0.010%

Awarding offices

Reported valueAwardsPositive obligationsShare
Barda - Aspr / Daappo / Barda Dcma(75A501)76$1.4B82.1%
National Institutes of Health Niaid(75N930)82$194.4M11.0%
National Institutes of Health Nida(75N950)15$55.2M3.1%
Fda Office of Acq Grant Svcs(75F401)29$23.3M1.3%
National Institutes of Health Nichd(75N940)42$11.4M0.65%
National Institutes of Health Olao(75N980)29$9.2M0.52%
Other reported values35$21.2M1.2%

Reported parent IDVs

Reported valueAwardsPositive obligationsShare
75N93021D00035(7529)3$37.2M2.1%
75A50122D00017(7505)8$27.6M1.6%
75N93021D00038(7529)3$21.9M1.3%
75N95024D00038(7529)1$14.8M0.84%
75A50122D00007(7505)4$11.1M0.63%
75A50123D00005(7505)1$8.0M0.45%
75N95023D00006(7529)1$7.4M0.42%
75N93019D00031(7529)2$6.1M0.34%
Other reported values111$87.9M5.0%
Not reported174$1.5B87.4%

Exact vehicle-match evidence

Reported award data linked 20 awards to a specific catalog vehicle.

Offers, award size, and timing

Median reported offers
2 median
216 reported · 92 not reported
Positive award obligations
$719K median
$114K–$2.6M middle 50%
Reported performance period
1,067 days (~2.9 years) median
308 reported · 0 not reported

Calculations group latest-period actions by award, retain awards with positive net obligations for share denominators, and use each award's latest reported USAspending procurement fields as of Sep 10, 2026. Blank competition, pricing, PSC, or parent-IDV values remain not reported; they are not inferred. Offer counts must be positive and below the FPDS 999 placeholder. Awarding organizations can differ from the funding agency that defines this page.

Top federal contractors

Latest 12-month market share, concentration, and complete prime contractor rankings across the period shown.

Prime contractor concentration
25 of 207prime contractors account for at least 80% of positive obligations in the last 12 months
Largest prime contractor
15.4%of positive obligations in the last 12 months
Leading four prime contractors
42.2%of positive obligations in the last 12 months
Leading eight prime contractors
56.0%of positive obligations in the last 12 months

Based on $1.7B in positive obligations during the 12 months ending Sep 10, 2026. Individual shares and movement appear in the searchable rankings below. Movement compares with Sep 11, 2024–Sep 10, 2025.

Last 12mo obligation volume: Highest positive obligations first; net deobligations follow by magnitude; contractors with no activity in the last 12 months follow by all-period obligations. Ranks use the complete contractor list and remain fixed when search narrows the results.

15 leading contractors
  1. #1

    Last 12mo obligations

    $267.9M

    15.4%

    Dollar movement

    +$180.5M

    vs. prior 12 months

    Last 12mo awards

    3 awards

    4 actions

    Historical and award details for ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE)
    Obligations: prior → latest
    $87.4M → $267.9M
    +206.4%
    Share: prior → latest
    6.0% → 15.4%
    +9.3 percentage points
    All-period obligations
    $498.6M
    4.1% of all-period positive obligations · 3 awards
    Recorded activity
    Since Nov 4, 2021
    through Aug 19, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside32
    Not reported00
    Reported small business00
    All-period set-aside types

    None reported.

  2. #2

    Last 12mo obligations

    $185.6M

    10.7%

    Dollar movement

    +$149.5M

    vs. prior 12 months

    Last 12mo awards

    1 award

    5 actions

    Historical and award details for START2 GROUP, INC.
    Obligations: prior → latest
    $36.1M → $185.6M
    +414.6%
    Share: prior → latest
    2.5% → 10.7%
    +8.2 percentage points
    All-period obligations
    $223.1M
    1.9% of all-period positive obligations · 1 award
    Recorded activity
    Since Apr 9, 2024
    through Sep 1, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside11
    Not reported00
    Reported small business11
    All-period set-aside types

    None reported.

  3. #3

    Last 12mo obligations

    $156.1M

    9.0%

    Dollar movement

    +$156.1M

    vs. prior 12 months

    Last 12mo awards

    1 award

    2 actions

    Historical and award details for SHIONOGI INC
    Obligations: prior → latest
    $0 → $156.1M
    Not comparable
    Share: prior → latest
    0% → 9.0%
    +9.0 percentage points
    All-period obligations
    $156.1M
    1.3% of all-period positive obligations · 1 award
    Recorded activity
    Since Apr 6, 2026
    through Aug 21, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside10
    Not reported00
    Reported small business00
    All-period set-aside types

    None reported.

  4. #4

    Last 12mo obligations

    $126.0M

    7.2%

    Dollar movement

    −$92.9M

    vs. prior 12 months

    Last 12mo awards

    1 award

    2 actions

    Historical and award details for AMGEN USA INC
    Obligations: prior → latest
    $218.9M → $126.0M
    −42.5%
    Share: prior → latest
    15.2% → 7.2%
    −7.9 percentage points
    All-period obligations
    $840.7M
    7.0% of all-period positive obligations · 2 awards
    Recorded activity
    Since Sep 28, 2022
    through Aug 4, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside12
    Not reported00
    Reported small business00
    All-period set-aside types

    None reported.

  5. #5

    Last 12mo obligations

    $79.6M

    4.6%

    Dollar movement

    +$11.8M

    vs. prior 12 months

    Last 12mo awards

    2 awards

    7 actions

    Historical and award details for BASILEA PHARMACEUTICA INTERNATIONAL LTD, ALLSCHWIL
    Obligations: prior → latest
    $67.8M → $79.6M
    +17.4%
    Share: prior → latest
    4.7% → 4.6%
    −0.1 percentage points
    All-period obligations
    $147.4M
    1.2% of all-period positive obligations · 2 awards
    Recorded activity
    Since Sep 18, 2024
    through Aug 4, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside21
    Not reported00
    Reported small business10
    All-period set-aside types

    None reported.

  6. #6

    Last 12mo obligations

    $58.1M

    3.3%

    Dollar movement

    +$58.1M

    vs. prior 12 months

    Last 12mo awards

    1 award

    2 actions

    Historical and award details for CIDARA THERAPEUTICS INC
    Obligations: prior → latest
    $0 → $58.1M
    Not comparable
    Share: prior → latest
    0% → 3.3%
    +3.3 percentage points
    All-period obligations
    $58.1M
    0.48% of all-period positive obligations · 1 award
    Recorded activity
    Since Sep 30, 2025
    through Jun 2, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside10
    Not reported00
    Reported small business10
    All-period set-aside types

    None reported.

  7. #7

    Last 12mo obligations

    $52.9M

    3.0%

    Dollar movement

    +$45.4M

    vs. prior 12 months

    Last 12mo awards

    1 award

    3 actions

    Historical and award details for PUBLIC HEALTH VACCINES LLC
    Obligations: prior → latest
    $7.5M → $52.9M
    +606.7%
    Share: prior → latest
    0.52% → 3.0%
    +2.5 percentage points
    All-period obligations
    $66.7M
    0.55% of all-period positive obligations · 1 award
    Recorded activity
    Since Nov 2, 2021
    through Jun 8, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside11
    Not reported00
    Reported small business11
    All-period set-aside types

    None reported.

  8. #8

    Last 12mo obligations

    $48.9M

    2.8%

    Dollar movement

    +$48.9M

    vs. prior 12 months

    Last 12mo awards

    1 award

    3 actions

    Historical and award details for OSSIUM HEALTH, INC.
    Obligations: prior → latest
    $0 → $48.9M
    Not comparable
    Share: prior → latest
    0% → 2.8%
    +2.8 percentage points
    All-period obligations
    $69.9M
    0.58% of all-period positive obligations · 1 award
    Recorded activity
    Since Aug 8, 2024
    through Sep 4, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside10
    Not reported00
    Reported small business10
    All-period set-aside types

    None reported.

  9. #9

    Last 12mo obligations

    $44.6M

    2.6%

    Dollar movement

    +$13.0M

    vs. prior 12 months

    Last 12mo awards

    21 awards

    49 actions

    Historical and award details for BATTELLE MEMORIAL INSTITUTE
    Obligations: prior → latest
    $31.6M → $44.6M
    +41.3%
    Share: prior → latest
    2.2% → 2.6%
    +0.4 percentage points
    All-period obligations
    $99.0M
    0.82% of all-period positive obligations · 28 awards
    Recorded activity
    Since Sep 23, 2022
    through Sep 8, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside01
    Not reported2112
    Reported small business00
    All-period set-aside types

    None reported.

  10. #10

    Last 12mo obligations

    $40.1M

    2.3%

    Dollar movement

    +$35.8M

    vs. prior 12 months

    Last 12mo awards

    7 awards

    11 actions

    Historical and award details for PPD DEVELOPMENT LP
    Obligations: prior → latest
    $4.3M → $40.1M
    +833.2%
    Share: prior → latest
    0.30% → 2.3%
    +2.0 percentage points
    All-period obligations
    $339.2M
    2.8% of all-period positive obligations · 11 awards
    Recorded activity
    Since Oct 28, 2021
    through Sep 3, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside33
    Not reported44
    Reported small business00
    All-period set-aside types

    None reported.

  11. #11

    Last 12mo obligations

    $38.4M

    2.2%

    Dollar movement

    −$11.6M

    vs. prior 12 months

    Last 12mo awards

    4 awards

    12 actions

    Historical and award details for MAPP BIOPHARMACEUTICAL, INC.
    Obligations: prior → latest
    $50.0M → $38.4M
    −23.1%
    Share: prior → latest
    3.5% → 2.2%
    −1.3 percentage points
    All-period obligations
    $348.6M
    2.9% of all-period positive obligations · 4 awards
    Recorded activity
    Since Nov 2, 2021
    through Aug 12, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside44
    Not reported00
    Reported small business22
    All-period set-aside types

    None reported.

  12. #12

    Last 12mo obligations

    $34.9M

    2.0%

    Dollar movement

    +$34.9M

    vs. prior 12 months

    Last 12mo awards

    1 award

    1 action

    Historical and award details for VERICEL CORPORATION
    Obligations: prior → latest
    $0 → $34.9M
    Not comparable
    Share: prior → latest
    0% → 2.0%
    +2.0 percentage points
    All-period obligations
    $34.9M
    0.29% of all-period positive obligations · 1 award
    Recorded activity
    Since Apr 1, 2026
    through Apr 1, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside10
    Not reported00
    Reported small business10
    All-period set-aside types

    None reported.

  13. #13

    Last 12mo obligations

    $33.2M

    1.9%

    Dollar movement

    +$1.1M

    vs. prior 12 months

    Last 12mo awards

    1 award

    1 action

    Historical and award details for CERUS CORPORATION
    Obligations: prior → latest
    $32.1M → $33.2M
    +3.5%
    Share: prior → latest
    2.2% → 1.9%
    −0.3 percentage points
    All-period obligations
    $65.4M
    0.54% of all-period positive obligations · 1 award
    Recorded activity
    Since Sep 20, 2024
    through Jul 21, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside11
    Not reported00
    Reported small business11
    All-period set-aside types

    None reported.

  14. #14

    Last 12mo obligations

    $31.7M

    1.8%

    Dollar movement

    +$31.7M

    vs. prior 12 months

    Last 12mo awards

    1 award

    2 actions

    Historical and award details for SPECTRAL MD, INC.
    Obligations: prior → latest
    $0 → $31.7M
    Not comparable
    Share: prior → latest
    0% → 1.8%
    +1.8 percentage points
    All-period obligations
    $86.6M
    0.72% of all-period positive obligations · 1 award
    Recorded activity
    Since Sep 27, 2023
    through Aug 17, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside10
    Not reported00
    Reported small business10
    All-period set-aside types

    None reported.

  15. #15

    Last 12mo obligations

    $25.9M

    1.5%

    Dollar movement

    +$19.0M

    vs. prior 12 months

    Last 12mo awards

    2 awards

    6 actions

    Historical and award details for LOCUS BIOSCIENCES INC
    Obligations: prior → latest
    $6.9M → $25.9M
    +273.2%
    Share: prior → latest
    0.48% → 1.5%
    +1.0 percentage points
    All-period obligations
    $70.8M
    0.59% of all-period positive obligations · 2 awards
    Recorded activity
    Since Nov 2, 2021
    through Aug 26, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside21
    Not reported00
    Reported small business10
    All-period set-aside types

    None reported.

Potential federal contract recompetes

Investigate potential recompetes surfaced by near-term end dates, award value, and recent contract changes.

RHO FEDERAL SYSTEMS DIVISION INC

EO14398; AUTOIMMUNE DISEASES STATISTICAL AND CLINICAL COORDINATING CENTER (ADSCCC)

The reported potential end date is Jan 31, 2027. Current award value is 100.0% of reported potential value ($40.1M of $40.1M).

Performance period

92.2%

As of Sep 10, 2026Potential end Jan 31, 2027

Current award value as a share of potential value

100.0%

$40.1M current$40.1M potential
Supporting data

Reported performance starts Feb 1, 2022.

No later potential end date is reported; current and potential end dates are both Jan 31, 2027.

$40.1M is obligated against $40.1M in current reported award value (100.0%).

Reported potential end dates: Jan 31, 2023 → Jan 31, 2024 → Jan 31, 2025 → Jan 31, 2026 → Jan 31, 2027.

Obligations are compared with current reported award value, not treated as a contract ceiling.

PIID 75N93022C00003

CRESTONE, INC.

TO ADMINISTRATE DE-OBLIGATE UNEXPENDED AND EXPIRING FISCAL YEAR 2021 FUNDING IN ACCORDANCE WITH 31 U.S.C. SECTION 1552 (A), IN PREPARATION FOR SEPTEMBER 30, 2026, CLOSING OF THE PERIOD OF AVAILABILITY OF THESE FISCAL YEAR FUNDS.

The reported potential end date is Jan 31, 2027. Current award value is 100.0% of reported potential value ($33.1M of $33.1M).

Performance period

94.7%

As of Sep 10, 2026Potential end Jan 31, 2027

Current award value as a share of potential value

100.0%

$33.1M current$33.1M potential
Supporting data

Reported performance starts Sep 9, 2019.

No later potential end date is reported; current and potential end dates are both Jan 31, 2027.

$33.1M is obligated against $33.1M in current reported award value (100.0%).

Reported potential end dates: Aug 11, 2023 → Oct 11, 2024 → Jan 31, 2026 → May 31, 2026 → Jan 31, 2027.

Obligations are compared with current reported award value, not treated as a contract ceiling.

PIID 75N93019C00056

VAXXAS PTY LTD

DEVELOPMENT OF HD-MICRO ARRAY PATCH (MAP) TO DELIVER A VACCINE AGAINST A PANDEMIC STRAIN OF INFLUENZA, H5N1.

The reported potential end date is Dec 30, 2026. Current award value is 100.0% of reported potential value ($29.6M of $29.6M).

Performance period

95.1%

As of Sep 10, 2026Potential end Dec 30, 2026

Current award value as a share of potential value

100.0%

$29.6M current$29.6M potential
Supporting data

Reported performance starts Sep 29, 2020.

No later potential end date is reported; current and potential end dates are both Dec 30, 2026.

$29.6M is obligated against $29.6M in current reported award value (100.0%).

Reported potential end dates: Jun 30, 2025 → Dec 30, 2026.

Obligations are compared with current reported award value, not treated as a contract ceiling.

PIID 75A50120C00180

LOCUS BIOSCIENCES INC

THE PURPOSE OF THIS BILATERAL MODIFICATION IS TO: 1. ADD $14,773,583.00 OF SUPPLEMENTAL FUNDING TO CLIN 0002. 2. ADD $3,226,417.00 OF SUPPLEMENTAL FUNDING TO CLIN 0003.

$73.9M is obligated on an award with a reported potential end date of January 1, 2027.

Performance period

95.1%

As of Sep 10, 2026Potential end Jan 1, 2027

Current award value as a share of potential value

67.3%

$73.9M current$109.8M potential
Supporting data

Reported performance starts Sep 28, 2020.

Current performance is reported through Dec 31, 2026.

$73.9M is obligated against $73.9M in current reported award value (100.0%).

Reported potential end dates: Jan 30, 2026 → Mar 30, 2026 → Dec 31, 2026 → Jan 1, 2027.

Obligations are compared with current reported award value, not treated as a contract ceiling.

PIID 75A50120C00169

ADVANCED TECHNOLOGY INTERNATIONAL

MODIFICATION UNDER RRPV OTA WITH ATI TO ADDRESS FUNDING GAPS IN INITIAL TASK ORDER.

$100.0M is obligated on an award with a reported potential end date of June 16, 2027.

Performance period

76.5%

As of Sep 10, 2026Potential end Jun 16, 2027

Current award value as a share of potential value

100.0%

$100.0M current$100.0M potential
Supporting data

Reported performance starts Mar 15, 2024.

No later potential end date is reported; current and potential end dates are both Jun 16, 2027.

$100.0M is obligated against $100.0M in current reported award value (100.0%).

Obligations are compared with current reported award value, not treated as a contract ceiling.

PIID 75A50124F61006

SEATTLE CHILDREN'S HOSPITAL

EO14398. IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CONSORTIUM.

The reported potential end date moved later 2 times in the latest 12 months.

Performance period

86.9%

As of Sep 10, 2026Potential end Sep 29, 2027

Current award value as a share of potential value

100.0%

$90.5M current$90.5M potential
Supporting data

Reported performance starts Sep 30, 2019.

No later potential end date is reported; current and potential end dates are both Sep 29, 2027.

$90.5M is obligated against $90.5M in current reported award value (100.0%).

Reported potential end dates: Sep 29, 2026 → Mar 31, 2027 → Sep 29, 2027.

Obligations are compared with current reported award value, not treated as a contract ceiling.

PIID 75N93019C00070

These are research leads, not confirmed recompetes. USAspending records through Sep 10, 2026; reported dates and values can change through later modifications.

Recent federal contract award activity

Recent contract actions with unusually large obligation changes or meaningful shifts in contractor and funding-office activity.

Base award

This action

+$223.8M

ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE)

BARDA - ASPR / DAAPPO / BARDA DCMA

STRATEGIC MARBURG ADVANCED RESEARCH AND DEVELOPMENT, PREPAREDNESS, REGISTRATION, EVALUATION AND PROCUREMENT (SMART-PREP)

Why it stands out

One action represented 12.8% of the market’s latest 12-month positive obligations.

At $223.8M, the action was large enough to materially affect the latest 12-month market picture.

Award net obligations
$263.6M
Share of 12-month positive obligations
12.8%
Supporting data
Prime contractor
#1 · 15.4% share
up 1 rank · +9.3 percentage points · $180.5M net increase; action exceeded it by $43.3M
Funding office
#1 · 74.8% attributed share
$43.0M net decline despite this positive action
Related:Largest share gainUnusually large action
PIID 75A50126C00001
Base award

This action

+$119.2M

SHIONOGI INC

BARDA - ASPR / DAAPPO / BARDA DCMA

LATE-STAGE DEVELOPMENT, FDA MARKETING AUTHORIZATION, PROCUREMENT, AND STOCKPILE OF ANTIBIOTICS FOR THE TREATMENT OF DRUG-RESISTANT SECONDARY BACTERIAL INFECTIONS AND/OR THE TREATMENT OR PEP OF INFECTIONS CAUSED BY BIOTHREAT PATHOGENS.

Why it stands out

No activity for this contractor was reported in this market during the preceding 12 months.

The base action placed the contractor #3 in this market by positive obligations over the latest 12 months.

Award net obligations
$156.1M
Share of 12-month positive obligations
6.8%
Supporting data
Prime contractor
#3 · 9.0% share
Newly active in this market; no actions were reported in the preceding 12 months
Funding office
#1 · 74.8% attributed share
$43.0M net decline despite this positive action
Related:Newly observed contractor cohortLargest newly observed contractor
PIID 75A50126C00004
Modification

This action

+$100.5M

START2 GROUP, INC.

BARDA - ASPR / DAAPPO / BARDA DCMA

OTHER TRANSACTION: START2 GROUP, INC. (75A50124C00012)

Why it stands out

This award grew while spending attributed to its office declined.

The modification added $100.5M while office-attributed obligations fell $43.0M overall.

Award net obligations
$223.1M
Share of 12-month positive obligations
5.8%
Supporting data
Prime contractor
#2 · 10.7% share
up 7 ranks · +8.2 percentage points · $149.5M net increase; action accounted for 67.2%
Funding office
#1 · 74.8% attributed share
$43.0M net decline despite this positive action
PIID 75A50124C00012 · Mod P00005
Base award

This action

+$58.1M

CIDARA THERAPEUTICS INC

BARDA - ASPR / DAAPPO / BARDA DCMA

DEVELOPMENT OF CD388 AS A LONG-LASTING PROPHYLACTIC ANTI-VIRAL OPTION FOR PROTECTION AGAINST THE HEALTH IMPACTS CAUSED BY INFLUENZA

Why it stands out

No activity for this contractor was reported in this market during the preceding 12 months.

The base action placed the contractor #6 in this market by positive obligations over the latest 12 months.

Award net obligations
$58.1M
Share of 12-month positive obligations
3.3%
Supporting data
Prime contractor
#6 · 3.3% share
Newly active in this market; no actions were reported in the preceding 12 months
Funding office
#1 · 74.8% attributed share
$43.0M net decline despite this positive action
Related:Newly observed contractor cohort
PIID 75A50125C00017
Modification

This action

+$32.6M

MAPP BIOPHARMACEUTICAL, INC.

OFC ASST SEC FOR PREPARENESS RES

THE PURPOSE OF THIS MODIFICATION IS TO: 1. FUND CLIN 0003A IN THE AMOUNT OF $32,580,161.00 2. UPDATE STATE OF WORK TO SUPPORT THE BUNDIBUGYO OUTBREAK RESPONSE 3. THE CONTRACT IS HEREBY DESIGNATED AS A DPAS RATED ORDER: DO-M3. ISSUE PRIORITY RATI

Why it stands out

The award grew alongside stronger office-attributed spending.

The modification added $32.6M while office-attributed obligations rose $84.1M overall.

Award net obligations
$220.6M
Share of 12-month positive obligations
1.9%
Supporting data
Prime contractor
#11 · 2.2% share
$11.6M net decline despite this positive action
Funding office
#3 · 7.5% attributed share
+4.8 percentage points · $84.1M net increase; action accounted for 38.8%
Related:Funding office gain
PIID 75A50122C00061 · Mod P00022
Modification

This action

+$66.0M

AMGEN USA INC

BARDA - ASPR / DAAPPO / BARDA DCMA

EO14398 FOR FAR 52.222-90, UPDATED HHSAR AND EXERCISE OPTION PERIOD 4A FOR $65,698,998.00

Why it stands out

This award grew while spending attributed to its office declined.

The modification added $66.0M while office-attributed obligations fell $43.0M overall.

Award net obligations
$839.9M
Share of 12-month positive obligations
3.8%
Supporting data
Prime contractor
#4 · 7.2% share
$92.9M net decline despite this positive action
Funding office
#1 · 74.8% attributed share
$43.0M net decline despite this positive action
PIID 75A50122C00065 · Mod P00008
View recent award activity by date (10)
  1. CERTARA UK LIMITEDBase award · PIID 75F40126C00071
    Action+$353K
    Award net obligations$353K
  2. BIOFIRE DEFENSE LLCModification · PIID 75A50122C00049
    Action+$202K
    Award net obligations$5.9M
  3. THE EMMES COMPANY, LLCModification · PIID 75N95022C00041
    Action+$1.5M
    Award net obligations$9.0M
  4. ADVANCED BIOSCIENCE LABORATORIES, INC.Base award · PIID 75N93026F00002
    Action+$1.0M
    Award net obligations$1.0M
  5. RADIANT DX INC.Deobligation · PIID 75N91025C00043
    Action−$55K
    Award net obligations$300K
  6. AURO VACCINES LLCDeobligation · PIID 75N93020C00040
    Action−$22K
    Award net obligations$10.7M
  7. EUROFINS DISCOVERY SERVICES NORTH AMERICA, LLCDeobligation · PIID 75N93021F00002
    Action>−$1
    Award net obligations$62K
  8. OSSIUM HEALTH, INC.Modification · PIID 75A50124C00032
    Action+$8.9M
    Award net obligations$69.9M
  9. OREXO US INCModification · PIID 75A50125C00010
    Action+$3.0M
    Award net obligations$11.5M
  10. UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOLModification · PIID 75N93024C00085
    Action+$1.2M
    Award net obligations$3.4M

HHS research and development in biotechnology (except nanobiotechnology) market FAQs

Answers based on reported federal contract data.

Who are the top HHS research and development in biotechnology (except nanobiotechnology) contractors?

In the 12 months through September 10, 2026, ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE), START2 GROUP, INC., and SHIONOGI INC were the leading HHS research and development in biotechnology (except nanobiotechnology) prime contractors by positive obligations.

  1. #1

    ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE)

    $267,885,121 in positive obligations

  2. #2

    START2 GROUP, INC.

    $185,575,980 in positive obligations

  3. #3

    SHIONOGI INC

    $156,103,541 in positive obligations

Rankings use reported USAspending award data.

Did HHS contract obligations increase under NAICS 541714?

Yes. Measured by net prime contract obligations, reported HHS activity in the research and development in biotechnology (except nanobiotechnology) market increased 20.9% from $1,390,216,579 in the preceding 12 months to $1,681,123,097 in the 12 months through September 10, 2026.

Latest 12 months
$1,681,123,097
Net prime contract obligations
Preceding 12 months
$1,390,216,579
Net prime contract obligations
Change
+20.9%
Between matched 12-month periods

Reported contract actions, not outlays or a forecast.

What recent HHS contract award activity was reported under NAICS 541714?

Recent HHS contract award activity reported in the research and development in biotechnology (except nanobiotechnology) market included actions for ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE), SHIONOGI INC, and START2 GROUP, INC. during the 12 months through September 10, 2026.

Action obligations are transaction-level amounts, not current award-level obligations.

Which procurement methods were reported for HHS contracts under NAICS 541714?

From September 11, 2025 through September 10, 2026, HHS reported 308 positive-obligation awards for research and development in biotechnology (except nanobiotechnology) under NAICS 541714. The leading award type was definitive contract. The leading reported procedure was np.

Positive-obligation awards
308
Leading reported procedure
Np
48.3% of positive obligations
Leading award type
Definitive Contract
87.1% of positive obligations
Full and open
47.1%
of positive obligations
Reported parent IDV
12.6%
of positive obligations
Observed vehicles
CARRRP and BARDA Nonclinical Development Biological
Exact matches from reported parent PIIDs

Percentages use positive obligations as the denominator.

Which HHS research and development in biotechnology (except nanobiotechnology) awards may warrant recompete research?

6 HHS research and development in biotechnology (except nanobiotechnology) awards may warrant recompete research based on reported potential-end dates, including awards held by RHO FEDERAL SYSTEMS DIVISION INC, CRESTONE, INC., and VAXXAS PTY LTD.

Research leads, not confirmed recompetes. Dates may change through later modifications.

Apply this research to a live pursuit

Sweetspot connects opportunity qualification, competitive research, capture, and proposal work in one workspace.

See Sweetspot in action

Related market research

Complete market indexes:

Same NAICS at other agencies:

Nearby NAICS at this agency:

Reported obligations include contract actions from October 1, 2021 through September 10, 2026. Set-aside and business-size fields reflect award records, not a contractor's current eligibility.

Review data methodology